LUME-Meso

Nintedanib Gains Promising Innovative Medicine Status in the UK

It was recently announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) designated nintedanib, an oral triple angiokinase inhibitor by Boehringer Ingelheim, as a Promising Innovative Medicine (PIM). Nintedanib is not yet available to malignant pleural #mesothelioma patients in the UK, but with this designation, the drug could be available to patients […]


Results Show Encouraging Survival Data: Nintedanib for Mesothelioma

On June 5, Anna Nowak, MD, PhD, of the University of Western Australia and member of the Meso Foundation’s Science Advisory Board, presented phase II results from LUME-Meso, a mesothelioma clinical trial sponsored by Boehringer Ingelheim, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
LUME-Meso is a randomized, double-blind, placebo-controlled trial evaluating […]